[go: up one dir, main page]

EA200801221A1 - Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк - Google Patents

Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк

Info

Publication number
EA200801221A1
EA200801221A1 EA200801221A EA200801221A EA200801221A1 EA 200801221 A1 EA200801221 A1 EA 200801221A1 EA 200801221 A EA200801221 A EA 200801221A EA 200801221 A EA200801221 A EA 200801221A EA 200801221 A1 EA200801221 A1 EA 200801221A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
low levels
cell dna
cell culture
viral vaccines
Prior art date
Application number
EA200801221A
Other languages
English (en)
Other versions
EA014062B1 (ru
Inventor
Йенс-Петер Грегерсен
Хольгер Кост
Original Assignee
Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг filed Critical Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг
Publication of EA200801221A1 publication Critical patent/EA200801221A1/ru
Publication of EA014062B1 publication Critical patent/EA014062B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к вакцинам для лечения или предотвращения вирусных инфекций. Кроме того, предложены способы снижения количества загрязняющих веществ, связанных с получением вакцин клеточных культур. Остаточная функциональная ДНК клеточных культур разрушают обработкой ДНК-алкилирующим агентом, таким как β-пропиолактон (БПЛ), тем самым способствуя получению вакцины, включающей иммуногенные белки, полученные из вируса, размноженного на клеточной культуре, по существу, свободной от остаточной функциональной ДНК клеточной культуры.
EA200801221A 2005-11-01 2006-11-01 Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк EA014062B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Publications (2)

Publication Number Publication Date
EA200801221A1 true EA200801221A1 (ru) 2008-10-30
EA014062B1 EA014062B1 (ru) 2010-08-30

Family

ID=37969762

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801221A EA014062B1 (ru) 2005-11-01 2006-11-01 Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк

Country Status (19)

Country Link
US (2) US10655108B2 (ru)
EP (3) EP2301572B1 (ru)
JP (5) JP5602366B2 (ru)
KR (1) KR20080081254A (ru)
CN (2) CN104474543A (ru)
AT (1) ATE494906T1 (ru)
AU (2) AU2006310171B2 (ru)
CA (1) CA2627971A1 (ru)
CY (1) CY1111378T1 (ru)
DE (1) DE602006019629D1 (ru)
DK (1) DK1951296T4 (ru)
EA (1) EA014062B1 (ru)
ES (2) ES2525518T3 (ru)
HK (1) HK1207828A1 (ru)
NZ (1) NZ567817A (ru)
PL (2) PL1951296T5 (ru)
PT (1) PT2301572E (ru)
SI (1) SI1951296T2 (ru)
WO (1) WO2007052163A2 (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052163A2 (en) * 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
JP6087041B2 (ja) 2006-01-27 2017-03-08 ノバルティス アーゲー 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
EA200970271A1 (ru) 2006-09-11 2010-02-26 Новартис Аг Получение вакцин против вируса гриппа без использования куриных эмбрионов
CA2692200A1 (en) * 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
KR20100135766A (ko) 2008-03-18 2010-12-27 노파르티스 아게 인플루엔자 바이러스 백신 항원 제조의 개선
JP2012507272A (ja) * 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
AU2010250832B2 (en) 2009-05-21 2013-10-03 Seqirus UK Limited Reverse genetics using non-endogenous pol I promoters
CA2769673A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
WO2011044576A2 (en) 2009-10-09 2011-04-14 Children's Medical Center Corporation Selectively disrupted whole-cell vaccine
EA023811B1 (ru) 2009-10-20 2016-07-29 Новартис Аг Способ получения вируса с использованием конструкции, кодирующей вирусную рнк
EP2566958B1 (en) 2010-05-03 2015-12-30 GlaxoSmithKline Biologicals S.A. Method for inactivating influenza virus
CA2796213A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Organic peroxide compounds for microorganism inactivation
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
EP2575872B1 (en) 2010-06-01 2020-08-19 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
ES2564096T3 (es) 2010-06-01 2016-03-17 Novartis Ag Concentración y liofilización de antígenos de vacuna contra la gripe
SG188947A1 (en) 2010-08-12 2013-06-28 Yisheng Biopharma Holdings Ltd Method for reducing dna impurities in viral compositions
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
CA2828192A1 (en) 2011-02-25 2012-08-30 Novartis Ag Exogenous internal positive control
MX363409B (es) * 2011-11-03 2019-03-20 Sentinext Therapeutics Sdn Bhd Antigenos y vacunas dirigidos contra enterovirus hunanos.
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
CA2813723A1 (en) 2012-03-02 2013-09-02 Novartis Ag Influenza virus reassortment
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
US20150161359A1 (en) 2012-06-04 2015-06-11 Novartis Ag Methods for safety testing
CA2893429A1 (en) 2012-12-03 2014-06-12 Synthetic Genomics Vaccines, Inc. Influenza virus reassortment
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
CN105828835A (zh) 2013-05-10 2016-08-03 诺华股份有限公司 避免流感疫苗中的发作性嗜睡病风险
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN105745218B (zh) * 2013-11-15 2020-11-06 诺华股份有限公司 去除残留细胞培养杂质
CN106661102B (zh) * 2014-05-28 2021-01-26 财团法人卫生研究院 作为对抗肠病毒感染之免疫原的病毒颗粒及其制造
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
CN114929270A (zh) * 2019-11-07 2022-08-19 塞其里斯英国有限公司 用于生产具有减小的颗粒大小的病毒疫苗的组合物和方法
WO2021099419A1 (en) 2019-11-18 2021-05-27 Seqirus UK Limited Method for producing reassortant influenza viruses
KR20230157397A (ko) * 2021-03-30 2023-11-16 덴카 주식회사 인플루엔자 백신
CN115354071A (zh) * 2022-08-10 2022-11-18 上海药明生基医药科技有限公司 一种检测重组腺相关病毒宿主细胞dna残留的方法
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用
TW202516000A (zh) * 2023-07-25 2025-04-16 日商Ｋｍ生物醫藥股份有限公司 利用雞蛋培養法進行的去活化流感疫苗的製備方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CH589453A5 (ru) * 1974-01-14 1977-07-15 Sandoz Ag
JP2661044B2 (ja) 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
CA2332455C (en) * 1998-06-01 2012-08-14 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
HK1044484B (en) * 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
BR0014281A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Vacina contra vìrus de gripe intranasal
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
WO2001041814A1 (en) 1999-12-08 2001-06-14 Crucell Holland B.V. Method of administering adenovirus
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
WO2002074336A2 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
AU2002254558A1 (en) 2001-04-27 2002-11-11 Becton, Dickinson And Company Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
KR101169468B1 (ko) 2002-04-26 2012-08-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드시스템
WO2004056979A2 (en) 2002-12-20 2004-07-08 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
WO2004092360A2 (en) 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
KR100908757B1 (ko) 2003-05-28 2009-07-22 위스콘신 얼럼나이 리서어치 화운데이션 백신 및 유전자 요법을 위한 고 역가 재조합 인플루엔자바이러스
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1780269B1 (en) 2004-02-23 2009-07-08 Crucell Holland B.V. Virus purification methods
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
BRPI0511152A (pt) 2004-05-20 2007-12-04 Id Biomedical Corp processo para a produção de uma vacina de influenza
ES2432655T3 (es) * 2004-09-09 2013-12-04 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados con antígenos de vacunas
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
AU2005322353B2 (en) 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
WO2007052163A2 (en) * 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
EP2615167A1 (en) * 2006-09-15 2013-07-17 MedImmune, LLC Method for eliminating DNA contaminants from viral preparations

Also Published As

Publication number Publication date
KR20080081254A (ko) 2008-09-09
EP2301572A1 (en) 2011-03-30
HK1129837A1 (en) 2009-12-11
DK1951296T3 (da) 2011-03-28
PL1951296T3 (pl) 2011-09-30
PL1951296T5 (pl) 2015-06-30
SI1951296T2 (sl) 2014-09-30
EP1951296A2 (en) 2008-08-06
BRPI0618094A8 (pt) 2017-08-22
CN101365480A (zh) 2009-02-11
JP6639077B2 (ja) 2020-02-05
CN101365480B (zh) 2014-11-05
JP2014198726A (ja) 2014-10-23
EP2301572B1 (en) 2014-09-10
EA014062B1 (ru) 2010-08-30
CN104474543A (zh) 2015-04-01
EP1951296B2 (en) 2014-07-23
SI1951296T1 (sl) 2011-04-29
CA2627971A1 (en) 2007-05-10
AU2006310171A1 (en) 2007-05-10
DE602006019629D1 (de) 2011-02-24
JP2020023557A (ja) 2020-02-13
PL2301572T3 (pl) 2015-02-27
US20090304729A1 (en) 2009-12-10
EP1951296B1 (en) 2011-01-12
PT2301572E (pt) 2014-12-22
ES2359214T5 (es) 2014-10-08
CY1111378T1 (el) 2015-08-05
JP2011256209A (ja) 2011-12-22
JP2016185988A (ja) 2016-10-27
WO2007052163A2 (en) 2007-05-10
AU2011201968A1 (en) 2011-05-19
BRPI0618094A2 (pt) 2011-08-16
AU2006310171B2 (en) 2011-02-17
NZ567817A (en) 2012-01-12
US10655108B2 (en) 2020-05-19
ES2359214T3 (es) 2011-05-19
AU2011201968B2 (en) 2014-08-28
ATE494906T1 (de) 2011-01-15
DK1951296T4 (da) 2014-09-01
JP5602366B2 (ja) 2014-10-08
US20200377864A1 (en) 2020-12-03
ES2525518T3 (es) 2014-12-26
US11466257B2 (en) 2022-10-11
HK1207828A1 (en) 2016-02-12
EP2842572A1 (en) 2015-03-04
JP7049761B2 (ja) 2022-04-07
JP2009513694A (ja) 2009-04-02
WO2007052163A3 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
EA200801221A1 (ru) Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
BR112012000942B8 (pt) processos para a produção de poliovírus, e para produzir uma vacina contra pólio
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
WO2005042728A3 (en) Immortalized avian cell lines for virus production
NZ598000A (en) Composition for treating hbv infection
EA202191537A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
ATE434035T1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
MX370690B (es) Epitopo de inmunizacion de nuevo virus de la influenza.
EA201100862A1 (ru) Новый изолят свиного цирковируса типа 2b и его применения
AR079710A1 (es) Proceso para el cultivo de celulas adherentes
NZ611531A (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
MX387420B (es) Producción de virus en cultivos celulares.
BRPI0914805B8 (pt) método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição
DE60143810D1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
EE200200157A (et) Vaktsiin
CL2024003076A1 (es) Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia
NO20081541L (no) Ny sjo-lus vaksine
WO2012040266A3 (en) Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
WO2012069190A3 (en) Depletion of host cell components from live virus vaccines
WO2014137249A3 (ru) Способ изготовления вакцины против ящура

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
PC4A Registration of transfer of a eurasian patent by assignment